CJC-1295 and Ipamorelin: The Complete Guide to Growth Hormone Peptide Therapy

Understanding Growth Hormone Decline: Why It Matters

Growth hormone (GH), produced by the anterior pituitary gland, is one of the most important hormones in the human body. It plays a central role in growth during childhood and adolescence, but its importance extends far beyond the growing years. Throughout adult life, growth hormone continues to influence body composition, metabolic function, tissue repair, bone density, cognitive function, sleep quality, and overall vitality. It is, in many ways, the body's master regenerative hormone, orchestrating the repair and renewal processes that keep tissues healthy and functional.

Unfortunately, growth hormone production declines steadily with age, a phenomenon known as somatopause. Beginning in the late twenties to early thirties, GH secretion decreases by approximately 14 percent per decade. By age 60, most adults produce only a fraction of the growth hormone they produced in their twenties. This decline is associated with many of the hallmark changes of aging, including increased body fat (particularly visceral abdominal fat), decreased lean muscle mass (sarcopenia), reduced bone density, thinning and less elastic skin, impaired cognitive function, decreased exercise capacity, and disrupted sleep patterns.

The recognition that declining growth hormone levels contribute to age-related deterioration has driven intense interest in strategies to restore or optimize GH levels. For decades, the primary approach was direct injection of synthetic human growth hormone (recombinant HGH), but this approach carries significant risks, is extremely expensive, and provides supraphysiological (above-normal) hormone levels that can lead to adverse effects. This is where growth hormone-releasing peptides like CJC-1295 and Ipamorelin enter the picture, offering a more nuanced and physiological approach to optimizing growth hormone levels.

What Is CJC-1295?

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), the natural hormone that signals the pituitary gland to produce and release growth hormone. To understand CJC-1295, it helps to first understand the natural GHRH pathway. In healthy individuals, the hypothalamus periodically releases GHRH, which travels to the anterior pituitary gland and stimulates the somatotroph cells to synthesize and secrete growth hormone. This release occurs in a pulsatile pattern, with the largest pulses occurring during deep sleep and smaller pulses throughout the day.

Natural GHRH has a very short half-life of only about seven minutes, which limits its therapeutic utility. CJC-1295 was developed to overcome this limitation. The peptide consists of the first 29 amino acids of GHRH (the bioactive portion) with four amino acid substitutions that protect it from enzymatic degradation. This modified peptide, known as CJC-1295 without DAC (Drug Affinity Complex), has a half-life of approximately 30 minutes, a significant improvement over natural GHRH but still requiring multiple daily administrations.

A further modification, CJC-1295 with DAC (also known as CJC-1295-DAC), adds a lysine residue linked to a reactive maleimido group that covalently binds to albumin in the bloodstream after injection. This albumin binding extends the half-life to approximately eight days, allowing for less frequent dosing (typically twice weekly). However, the extended half-life of CJC-1295 with DAC results in a continuous elevation of growth hormone levels rather than the natural pulsatile pattern, which has led many practitioners to prefer CJC-1295 without DAC (often simply called Modified GRF 1-29) for a more physiological growth hormone release profile.

How CJC-1295 Stimulates Growth Hormone

CJC-1295 works by binding to the GHRH receptor on pituitary somatotroph cells, the same receptor targeted by natural GHRH. When CJC-1295 binds this receptor, it activates intracellular signaling cascades that stimulate the production and release of growth hormone. Importantly, CJC-1295 amplifies the body's natural growth hormone pulses rather than creating an artificial, constant elevation. This means that the pulsatile pattern of GH release, which is important for optimal physiological effects, is maintained when CJC-1295 is administered appropriately. The peptide essentially turns up the volume on the body's existing GH signaling system rather than bypassing it entirely.

What Is Ipamorelin?

Ipamorelin is a synthetic peptide that belongs to the class of growth hormone secretagogues (GHSs), specifically acting as a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist. Unlike CJC-1295, which mimics GHRH and acts on the GHRH receptor, Ipamorelin acts on a completely different receptor, the ghrelin receptor (also known as the GHS-R1a receptor). This distinction is important because it means that CJC-1295 and Ipamorelin stimulate growth hormone release through two independent and complementary pathways.

Ghrelin is a hormone produced primarily in the stomach that is often referred to as the "hunger hormone" due to its role in stimulating appetite. However, ghrelin also has potent growth hormone-releasing effects. When ghrelin binds to GHSR on pituitary somatotroph cells, it stimulates GH release through mechanisms that are distinct from and additive to those activated by GHRH. Ipamorelin is a pentapeptide (five amino acids) that was specifically designed to activate the ghrelin receptor and stimulate GH release while minimizing the appetite-stimulating and cortisol-releasing effects associated with ghrelin and some other GH secretagogues.

What Makes Ipamorelin Unique Among GH Secretagogues

Ipamorelin's selectivity is its defining characteristic and the reason it has become the preferred GH secretagogue among many peptide therapy practitioners. Earlier GH secretagogues, such as GHRP-6 and GHRP-2, also stimulate GH release via the ghrelin receptor but have significant additional effects that can be undesirable. GHRP-6, for example, causes a pronounced increase in appetite (which can be counterproductive for patients seeking body composition improvements) and also stimulates the release of cortisol and prolactin. GHRP-2 has intermediate selectivity, with less appetite stimulation than GHRP-6 but more than Ipamorelin.

Ipamorelin, by contrast, stimulates GH release with minimal effects on appetite, cortisol, or prolactin. This selectivity makes it a cleaner and more predictable peptide, with fewer side effects and a more favorable risk-benefit profile. Research has shown that Ipamorelin produces dose-dependent increases in GH release without causing the spikes in cortisol, ACTH, or prolactin seen with other GH secretagogues. This selectivity has made Ipamorelin the gold standard among GH secretagogues in clinical peptide therapy practice.

The CJC-1295/Ipamorelin Combination: Synergy in Action

The combination of CJC-1295 and Ipamorelin has become one of the most popular peptide therapy protocols for growth hormone optimization, and for good reason. The two peptides work through different receptor systems and different intracellular signaling pathways, and when combined, they produce a synergistic effect on GH release that exceeds what either peptide can achieve alone.

To use an analogy, imagine the pituitary gland as a factory that produces growth hormone. CJC-1295 acts like a work order, telling the factory to ramp up production and prepare to ship product. Ipamorelin acts like the shipping signal, triggering the actual release of the growth hormone that has been produced. When both signals are present simultaneously, the factory produces more GH and releases it more efficiently, resulting in a larger and more robust GH pulse than either signal could produce on its own.

Research supports this synergistic effect. Studies have shown that combining a GHRH analog with a ghrelin receptor agonist produces GH pulses that are significantly larger than those produced by either agent alone. This amplified GH response translates into greater clinical benefits while still maintaining the physiological pulsatile release pattern that is important for optimal tissue effects. The combination also allows for lower doses of each individual peptide, which can help minimize any dose-related side effects.

Benefits of CJC-1295/Ipamorelin Therapy

The benefits of CJC-1295/Ipamorelin therapy are extensive and reflect the broad range of physiological processes influenced by growth hormone. While individual responses vary, the following benefits have been consistently reported by practitioners and patients.

Improved Body Composition: Muscle Growth and Fat Loss

Perhaps the most sought-after benefit of CJC-1295/Ipamorelin therapy is its effect on body composition. Growth hormone is a powerful regulator of body composition, promoting lean muscle mass while facilitating the breakdown and utilization of stored body fat. When GH levels are optimized through CJC-1295/Ipamorelin therapy, patients typically experience a gradual increase in lean muscle mass and a reduction in body fat percentage, particularly in the stubborn visceral (abdominal) fat depot that is most strongly associated with metabolic disease risk.

The mechanism by which GH promotes fat loss involves several pathways. GH stimulates lipolysis, the breakdown of triglycerides stored in adipose tissue into free fatty acids and glycerol, making them available as fuel for energy production. It also promotes the oxidation (burning) of these fatty acids in muscle and liver tissue. Simultaneously, GH enhances protein synthesis in muscle tissue, providing the building blocks for muscle growth and repair. This dual action on fat and muscle results in favorable body composition changes even in the absence of dramatic changes in total body weight, as the body shifts from a fat-dominant to a lean-dominant composition.

These body composition benefits are enhanced when CJC-1295/Ipamorelin therapy is combined with regular exercise, particularly resistance training, and adequate protein intake. Growth hormone amplifies the body's adaptive response to exercise, meaning that the same workout produces greater results when GH levels are optimized. Many patients report that they see improvements in muscle tone and definition, reduced waist circumference, and a more youthful body composition within the first two to three months of therapy.

Enhanced Sleep Quality

One of the earliest and most consistently reported benefits of CJC-1295/Ipamorelin therapy is improved sleep quality. Growth hormone and sleep have a bidirectional relationship: the largest natural GH pulses occur during deep (slow-wave) sleep, and GH itself promotes deeper, more restorative sleep. As GH levels decline with age, sleep quality often deteriorates, creating a vicious cycle where poor sleep further reduces GH production.

CJC-1295/Ipamorelin therapy, particularly when the evening dose is timed appropriately (typically administered before bedtime), can help break this cycle. Many patients report falling asleep more quickly, experiencing deeper and more restful sleep, waking less frequently during the night, and feeling more refreshed upon waking. These improvements in sleep quality are often noticed within the first one to two weeks of therapy and are among the first benefits patients experience. Improved sleep has cascading benefits for virtually every aspect of health, including cognitive function, immune function, mood, energy levels, and exercise recovery.

Skin Health and Anti-Aging Effects

Growth hormone plays a significant role in maintaining skin health by promoting collagen synthesis, maintaining skin thickness and elasticity, and supporting the skin's natural repair mechanisms. As GH levels decline with age, skin becomes thinner, less elastic, and more prone to wrinkles and sagging. CJC-1295/Ipamorelin therapy can help counteract these changes by restoring more youthful GH levels and their beneficial effects on skin biology.

Patients undergoing CJC-1295/Ipamorelin therapy commonly report improvements in skin texture, reduced appearance of fine lines, improved skin hydration, and a more youthful overall appearance. These changes typically become noticeable after three to six months of consistent therapy, reflecting the time needed for increased collagen production to manifest as visible skin improvements. While CJC-1295/Ipamorelin is not a substitute for a comprehensive skincare regimen, it can be a valuable component of an anti-aging strategy that addresses skin health from the inside out.

Recovery and Healing

Growth hormone is essential for tissue repair and recovery, which is why injuries heal more slowly as we age and GH levels decline. By optimizing GH levels, CJC-1295/Ipamorelin therapy can enhance the body's ability to recover from exercise, injuries, and surgical procedures. Athletes and active individuals frequently report faster recovery between workouts, reduced muscle soreness, and the ability to train more frequently and intensely when using CJC-1295/Ipamorelin. These recovery benefits are mediated by GH's effects on protein synthesis, collagen production, and immune function, all of which are critical for tissue repair and regeneration.

Cognitive Function and Mood

Growth hormone receptors are found throughout the brain, and GH has been shown to influence cognitive function, neuroprotection, and mood regulation. Patients on CJC-1295/Ipamorelin therapy commonly report improvements in mental clarity, focus, memory, and overall cognitive function. Some patients also report improvements in mood, including reduced anxiety and a greater sense of overall well-being. While these cognitive and mood benefits are less rigorously documented than the body composition effects, they are consistently reported in clinical practice and are consistent with the known neurological effects of growth hormone.

Dosing Protocols: How CJC-1295/Ipamorelin Is Used

Dosing protocols for CJC-1295/Ipamorelin vary among practitioners, but the following represents the most common approach used in clinical practice. It is essential to emphasize that these protocols should only be followed under the guidance of a qualified healthcare provider who can customize dosing based on individual needs, health status, and response to therapy.

Standard Dosing Protocol

The most common protocol involves combining CJC-1295 (without DAC, also known as Modified GRF 1-29) with Ipamorelin, typically at a dose of 100 to 300 micrograms (mcg) of each peptide, administered via subcutaneous injection. The standard protocol involves one to two injections per day, with the most common timing being before bedtime and optionally in the morning. The bedtime dose capitalizes on the natural nocturnal GH pulse, amplifying it for maximum benefit, while the morning dose (if used) provides an additional GH pulse that supports daytime energy and metabolic function.

For patients using CJC-1295 with DAC, the dosing protocol is different due to the longer half-life. Typical doses range from 1,000 to 2,000 mcg (1 to 2 mg) administered one to two times per week. As noted earlier, the extended half-life of the DAC version creates a more sustained elevation of GH rather than the pulsatile pattern seen with the non-DAC version. Some practitioners prefer the DAC version for its convenience (fewer injections), while others prefer the non-DAC version for its more physiological GH release pattern.

Cycling Protocols

Many practitioners recommend cycling CJC-1295/Ipamorelin therapy rather than using it continuously. A common cycling protocol involves using the peptides for five days per week with two days off, or for eight to twelve weeks followed by a break of two to four weeks. The rationale for cycling is to prevent desensitization of the pituitary gland to the peptide stimulation, which could theoretically reduce the magnitude of the GH response over time. However, the evidence for pituitary desensitization with these peptides is not definitive, and some practitioners prescribe continuous use without cycling, particularly at lower doses. The optimal cycling strategy likely varies among individuals and is an area where clinical experience and patient response guide the approach.

Timing Considerations

The timing of CJC-1295/Ipamorelin injections is important for maximizing their effects. Growth hormone release is influenced by several factors, including blood sugar levels, exercise, and sleep. GH secretion is suppressed by elevated blood glucose and insulin levels, so injections should be administered on an empty stomach or at least two to three hours after eating. The bedtime injection should ideally be taken at least 90 minutes after the last meal of the day. Exercise also potentiates GH release, so some practitioners recommend timing an injection to coincide with or immediately follow a workout for an enhanced GH response.

CJC-1295/Ipamorelin vs. Synthetic HGH: A Critical Comparison

For patients considering growth hormone optimization, one of the most important comparisons is between CJC-1295/Ipamorelin therapy and direct injection of synthetic human growth hormone (recombinant HGH, brands like Norditropin, Genotropin, and Humatrope). While both approaches aim to address growth hormone deficiency or optimize GH levels, they differ significantly in their mechanism, safety profile, cost, and clinical outcomes.

Mechanism: Stimulation vs. Replacement

The fundamental difference between the two approaches is that CJC-1295/Ipamorelin stimulates the body's own pituitary gland to produce and release more growth hormone, while synthetic HGH bypasses the pituitary entirely by directly injecting exogenous growth hormone into the body. This distinction has several important implications. CJC-1295/Ipamorelin maintains the body's natural feedback mechanisms, meaning the pituitary gland can still modulate GH production in response to the body's needs. When GH levels rise to appropriate levels, the body's feedback systems reduce further release, providing a natural ceiling that prevents excessive GH accumulation. Synthetic HGH, by contrast, provides a fixed dose of growth hormone regardless of the body's current needs, and the body's feedback mechanisms cannot modulate the exogenous hormone that has been injected.

This difference in mechanism translates into a more physiological GH profile with CJC-1295/Ipamorelin. The pulsatile release pattern is maintained, with natural peaks and troughs that mimic the body's youthful GH secretion pattern. Synthetic HGH produces a spike in GH levels followed by a gradual decline, which does not replicate the natural pulsatile pattern. Some researchers believe that the pulsatile pattern is important for optimal tissue responsiveness to GH and that the continuous exposure provided by exogenous HGH may lead to GH receptor downregulation over time.

Safety Profile

Synthetic HGH at supraphysiological doses has been associated with a range of side effects, including fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, increased risk of type 2 diabetes, and theoretically, increased cancer risk (though this remains debated). These side effects are largely related to the supraphysiological GH levels that can occur with direct HGH injection, particularly at higher doses.

CJC-1295/Ipamorelin, by stimulating the body's own GH production within physiological limits, carries a lower risk of these side effects. The body's natural feedback mechanisms provide a safety check that prevents GH levels from rising to dangerous levels. Side effects of CJC-1295/Ipamorelin are generally mild and include injection site reactions, transient flushing, headache, and occasional water retention. Serious side effects are uncommon when the peptides are used at recommended doses under medical supervision.

Cost Comparison

Synthetic HGH is one of the most expensive medications available, with costs typically ranging from $800 to $3,000 or more per month depending on the dose and brand. CJC-1295/Ipamorelin therapy is significantly less expensive, typically ranging from $200 to $500 per month through compounding pharmacies. This substantial cost difference makes CJC-1295/Ipamorelin a more accessible option for many patients, particularly those who are not candidates for insurance coverage of HGH therapy (which is generally only covered for documented growth hormone deficiency based on specific diagnostic criteria).

Legal and Regulatory Considerations

Synthetic HGH is a controlled substance in many jurisdictions and is subject to strict prescribing regulations. It is FDA-approved for specific medical conditions, including adult growth hormone deficiency, but off-label use for anti-aging or performance enhancement is not only unapproved but illegal under federal law in the United States. CJC-1295 and Ipamorelin are not FDA-approved for any medical condition but have been available through compounding pharmacies with a prescription. The regulatory status of these peptides has been evolving, and patients should work with knowledgeable providers who stay current with regulatory developments.

Timeline of Results: What to Expect

Setting realistic expectations for CJC-1295/Ipamorelin therapy is important for patient satisfaction and adherence. While individual responses vary, the following timeline represents the general pattern of benefits typically observed in clinical practice.

Weeks 1 to 4: Early Changes

The earliest benefits are often related to sleep quality and overall sense of well-being. Many patients notice improved sleep depth and quality within the first one to two weeks. Increased energy levels and a sense of improved vitality are also commonly reported during this early phase. Some patients notice mild fluid retention, which is a normal response to increased GH activity and typically resolves or stabilizes. Visible body composition changes are generally not yet apparent during this phase, though some patients report subtle improvements in skin appearance.

Months 1 to 3: Building Momentum

During this phase, the benefits of therapy become more noticeable and consistent. Energy levels continue to improve, exercise recovery is enhanced, and many patients find that they can train harder and more frequently. Body composition changes begin to emerge, with gradual reductions in body fat and increases in lean muscle mass becoming apparent. Improvements in skin texture and appearance become more noticeable. Cognitive benefits, including improved focus and mental clarity, are often reported during this phase. Patients who are combining CJC-1295/Ipamorelin therapy with a structured exercise and nutrition program typically see the most pronounced improvements during this period.

Months 3 to 6: Peak Benefits Emerging

By the three to six month mark, the full range of CJC-1295/Ipamorelin benefits is typically evident. Body composition improvements are clearly visible, with patients reporting noticeable fat loss, improved muscle definition, and a more youthful physique. Hair and nail growth may be accelerated. Skin quality continues to improve, with reduced appearance of fine lines and improved elasticity. Sleep quality is consistently better, and patients often describe a level of energy and vitality that they haven't experienced in years. Laboratory testing may reveal improvements in IGF-1 levels (a marker of GH activity), lipid profiles, and inflammatory markers.

Months 6 and Beyond: Sustained Benefits

With continued therapy, the benefits of CJC-1295/Ipamorelin are generally maintained and may continue to improve incrementally. Long-term users often report sustained improvements in body composition, energy, sleep, and skin quality. The anti-aging benefits become increasingly apparent with longer treatment duration, as the cumulative effects of optimized GH levels on collagen production, bone density, and cellular repair processes become more pronounced. Regular monitoring by a healthcare provider, including periodic laboratory testing, is important for ensuring that the therapy continues to be effective and safe over time.

Legal Status and Finding a Provider

Navigating the legal and regulatory landscape for CJC-1295/Ipamorelin therapy is an important part of the process for any patient considering these peptides. The regulatory environment for compounded peptides has been evolving rapidly, and staying informed is essential for both patients and providers.

Current Regulatory Status

Neither CJC-1295 nor Ipamorelin is FDA-approved for any medical indication. They have been available through compounding pharmacies that produce customized medications based on individual prescriptions. The FDA's evolving regulatory posture toward compounded peptides has created some uncertainty regarding the ongoing availability of these peptides through compounding pharmacies. Patients should work with providers who are knowledgeable about the current regulatory status and who source peptides from reputable pharmacies that adhere to rigorous quality standards.

It is also worth noting that CJC-1295 and Ipamorelin are prohibited in competitive sports by the World Anti-Doping Agency (WADA) and most professional sports organizations. Athletes subject to anti-doping testing should not use these peptides, as they will result in a positive test and potential sanctions.

Choosing a Qualified Provider

Finding a qualified provider for CJC-1295/Ipamorelin therapy is essential for safe and effective treatment. Look for a licensed healthcare provider (MD, DO, NP, PA, or ND) with specific training or experience in peptide therapy, hormone optimization, or anti-aging medicine. Many qualified providers have completed specialized training programs in peptide therapy and hold certifications in anti-aging or regenerative medicine. A good provider will conduct a comprehensive evaluation before prescribing, including detailed medical history, physical examination, and laboratory testing that typically includes IGF-1 levels, comprehensive metabolic panel, lipid panel, thyroid function, testosterone levels, and other relevant markers.

The provider should also clearly explain the expected benefits, potential risks, dosing protocol, and monitoring plan. They should use peptides sourced from reputable compounding pharmacies that perform third-party purity and potency testing. Beware of providers who prescribe peptides without a thorough evaluation, who make unrealistic claims about results, or who source peptides from unregulated or unverified suppliers.

Using PeptideProbe to Find a Provider

PeptideProbe's clinic directory is specifically designed to help patients find qualified peptide therapy providers. You can search for providers who offer CJC-1295/Ipamorelin therapy in your area, view their credentials and specialties, read patient reviews, and compare multiple providers before making a decision. Our directory prioritizes providers who demonstrate a commitment to quality, safety, and evidence-based practice. Whether you are new to peptide therapy or are looking for a new provider, PeptideProbe can help you find a qualified practitioner to guide your growth hormone optimization journey.

Frequently Asked Questions About CJC-1295/Ipamorelin

Are CJC-1295 and Ipamorelin safe?

Based on the available research and clinical experience, CJC-1295 and Ipamorelin have a favorable safety profile when used at recommended doses under medical supervision. The most common side effects are mild and include injection site reactions, transient flushing, headache, and occasional water retention. Serious side effects are uncommon. However, large-scale, long-term human safety studies have not been conducted, and patients should be monitored regularly by their healthcare provider. Patients with active cancers, pregnant or breastfeeding women, and those with certain medical conditions should not use these peptides without careful evaluation and consultation with their healthcare team.

How long do I need to use CJC-1295/Ipamorelin to see results?

Most patients begin to notice improvements in sleep quality and energy levels within the first two to four weeks. Body composition changes typically become apparent within two to three months, and the full range of benefits generally emerges over three to six months of consistent use. Patience and consistency are key, as the benefits of optimized growth hormone levels accrue gradually over time. Combining therapy with regular exercise, adequate nutrition (particularly protein intake), quality sleep, and stress management will maximize and accelerate results.

Can I combine CJC-1295/Ipamorelin with other peptides or treatments?

Yes, CJC-1295/Ipamorelin is often combined with other peptides and treatments as part of a comprehensive optimization protocol. Common combinations include BPC-157 for enhanced healing and recovery, thymosin beta-4 (TB-500) for tissue repair, and various other peptides depending on the patient's goals and medical situation. Some practitioners also combine CJC-1295/Ipamorelin with testosterone replacement therapy, nutritional supplementation, and lifestyle interventions for a comprehensive anti-aging approach. All combinations should be managed by a qualified healthcare provider who can ensure compatibility and appropriate monitoring.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC (Drug Affinity Complex) has a much longer half-life (approximately eight days) compared to CJC-1295 without DAC (approximately 30 minutes). The DAC version provides a sustained elevation of growth hormone and requires less frequent dosing (one to two times per week), while the non-DAC version produces more distinct GH pulses and is typically dosed one to two times daily. Many practitioners prefer the non-DAC version because its pulsatile GH release pattern more closely mimics the body's natural GH secretion. The choice between the two depends on individual goals, preferences, and the clinical judgment of the prescribing provider.

Will CJC-1295/Ipamorelin show up on a drug test?

CJC-1295 and Ipamorelin are not standard panel drug test targets in workplace drug testing. However, they are prohibited substances under WADA regulations and in most professional and amateur sports organizations. Specialized anti-doping tests can detect these peptides. Athletes subject to drug testing should not use CJC-1295/Ipamorelin and should discuss any peptide use with their sports organization or anti-doping authority.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. CJC-1295 and Ipamorelin are not approved by the FDA for any medical condition. The information presented here is based on preclinical research, limited clinical data, and clinical observations and should not be used as a substitute for professional medical guidance. Always consult with a qualified healthcare provider before starting any new treatment, including peptide therapy. Individual results may vary, and the long-term safety and efficacy of CJC-1295 and Ipamorelin in humans have not been established through large-scale clinical trials. These peptides are prohibited in competitive sports and should not be used by athletes subject to anti-doping testing.